Insulin Independence in Newly Diagnosed Type 1 Diabetes Patient following Fenofibrate Treatment

A 19-year-old girl was diagnosed with type 1 diabetes and showing polydipsia and polyuria. She was double autoantibody-positive and had a diabetes-prone tissue type. She was immediately started on insulin. Fenofibrate treatment (160 mg daily) was initiated seven days after diagnosis. The need for in...

Full description

Saved in:
Bibliographic Details
Main Authors: Karsten Buschard, Laurits J. Holm, Ulla Feldt-Rasmussen
Format: Article
Language:English
Published: Wiley 2020-01-01
Series:Case Reports in Medicine
Online Access:http://dx.doi.org/10.1155/2020/6865190
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832560683383783424
author Karsten Buschard
Laurits J. Holm
Ulla Feldt-Rasmussen
author_facet Karsten Buschard
Laurits J. Holm
Ulla Feldt-Rasmussen
author_sort Karsten Buschard
collection DOAJ
description A 19-year-old girl was diagnosed with type 1 diabetes and showing polydipsia and polyuria. She was double autoantibody-positive and had a diabetes-prone tissue type. She was immediately started on insulin. Fenofibrate treatment (160 mg daily) was initiated seven days after diagnosis. The need for insulin quickly declined, and she took her last dose of insulin 19 days after the first dose of fenofibrate, having regained endogenous control of blood glucose concentrations. She has now been insulin independent for one year and 9 months. Unstimulated C-peptide has increased by 51% (317 to 479 pmol/l), and IA-2 autoantibody level has decreased by 65% (49 to 17 × 103 arbitrary units). Fenofibrate is a widely used drug for reducing triglyceride and cholesterol levels. Fenofibrate reverses and prevents autoimmune diabetes in nonobese diabetic (NOD) mice by increasing the amount of the sphingolipid sulfatide in islets. Sphingolipid metabolism is otherwise abnormal in the islets at diagnosis of type 1 diabetes. In conclusion, we describe a 19-year-old patient with classical newly diagnosed type 1 diabetes, which following fenofibrate treatment has been without insulin for 21 months.
format Article
id doaj-art-9a1fc3e29a0e402bb3f7707bc4fd0bd4
institution Kabale University
issn 1687-9627
1687-9635
language English
publishDate 2020-01-01
publisher Wiley
record_format Article
series Case Reports in Medicine
spelling doaj-art-9a1fc3e29a0e402bb3f7707bc4fd0bd42025-02-03T01:27:04ZengWileyCase Reports in Medicine1687-96271687-96352020-01-01202010.1155/2020/68651906865190Insulin Independence in Newly Diagnosed Type 1 Diabetes Patient following Fenofibrate TreatmentKarsten Buschard0Laurits J. Holm1Ulla Feldt-Rasmussen2The Bartholin Institute, Department of Pathology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, DenmarkThe Bartholin Institute, Department of Pathology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, DenmarkDepartment of Medical Endocrinology and Metabolism, Rigshospitalet, Copenhagen University Hospital, Copenhagen, DenmarkA 19-year-old girl was diagnosed with type 1 diabetes and showing polydipsia and polyuria. She was double autoantibody-positive and had a diabetes-prone tissue type. She was immediately started on insulin. Fenofibrate treatment (160 mg daily) was initiated seven days after diagnosis. The need for insulin quickly declined, and she took her last dose of insulin 19 days after the first dose of fenofibrate, having regained endogenous control of blood glucose concentrations. She has now been insulin independent for one year and 9 months. Unstimulated C-peptide has increased by 51% (317 to 479 pmol/l), and IA-2 autoantibody level has decreased by 65% (49 to 17 × 103 arbitrary units). Fenofibrate is a widely used drug for reducing triglyceride and cholesterol levels. Fenofibrate reverses and prevents autoimmune diabetes in nonobese diabetic (NOD) mice by increasing the amount of the sphingolipid sulfatide in islets. Sphingolipid metabolism is otherwise abnormal in the islets at diagnosis of type 1 diabetes. In conclusion, we describe a 19-year-old patient with classical newly diagnosed type 1 diabetes, which following fenofibrate treatment has been without insulin for 21 months.http://dx.doi.org/10.1155/2020/6865190
spellingShingle Karsten Buschard
Laurits J. Holm
Ulla Feldt-Rasmussen
Insulin Independence in Newly Diagnosed Type 1 Diabetes Patient following Fenofibrate Treatment
Case Reports in Medicine
title Insulin Independence in Newly Diagnosed Type 1 Diabetes Patient following Fenofibrate Treatment
title_full Insulin Independence in Newly Diagnosed Type 1 Diabetes Patient following Fenofibrate Treatment
title_fullStr Insulin Independence in Newly Diagnosed Type 1 Diabetes Patient following Fenofibrate Treatment
title_full_unstemmed Insulin Independence in Newly Diagnosed Type 1 Diabetes Patient following Fenofibrate Treatment
title_short Insulin Independence in Newly Diagnosed Type 1 Diabetes Patient following Fenofibrate Treatment
title_sort insulin independence in newly diagnosed type 1 diabetes patient following fenofibrate treatment
url http://dx.doi.org/10.1155/2020/6865190
work_keys_str_mv AT karstenbuschard insulinindependenceinnewlydiagnosedtype1diabetespatientfollowingfenofibratetreatment
AT lauritsjholm insulinindependenceinnewlydiagnosedtype1diabetespatientfollowingfenofibratetreatment
AT ullafeldtrasmussen insulinindependenceinnewlydiagnosedtype1diabetespatientfollowingfenofibratetreatment